[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334612-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334612-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","screening-for-lung-cancer-with-computed-tomography-protocol-for-systematic-reviews-canadian-task-force-on-preventive-health-care","Screening for lung cancer with computed tomography - protocol for systematic reviews - Canadian Task Force on Preventive Health Care","","Purpose: Lung cancer causes the leading cancer deaths in Canada, and early disease is often asymptomatic; screening aims to reduce mortality by detecting cancer earlier when treatment is more curative. This protocol guides updated evidence reviews for the Canadian Task Force on Preventive Health Care. Methods: Updates include CT screening benefits/harms and de novo comparative analyses of selection criteria, risk models, and nodule classification systems, using predefined databases and study selection rules, with dual screening and GRADE certainty assessment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/screening-for-lung-cancer-with-computed-tomography-protocol-for-systematic-reviews-canadian-task-force-on-preventive-health-care/334612/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/screening-for-lung-cancer-with-computed-tomography-protocol-for-systematic-reviews-canadian-task-force-on-preventive-health-care/334612.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of this protocol for lung cancer screening?","Question",{"text":63,"@type":64},"It aims to prevent lung cancer mortality by enabling earlier detection through computed tomography screening, and to inform updated recommendations for the Canadian Task Force on Preventive Health Care.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which comparative questions will the review address?",{"text":68,"@type":64},"It will compare trial-based selection criteria versus risk prediction models, and trial-based nodule classification versus other classification systems, and also assess patient values and preferences.",{"name":70,"@type":61,"acceptedAnswer":71},"How will evidence quality and study bias be assessed?",{"text":72,"@type":64},"Two reviewers will independently assess within- and across-study risk of bias and rate certainty using GRADE, then reach consensus.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334612,1790174531,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Pillay et al. Systematic Reviews (2024) 13:88 [https://doi.org/10.1186/s13643-024-02506-3](https://doi.org/10.1186/s13643-024-02506-3)  \nSystematic Reviews  \n PROTOCOL Open Access  \nScreening for lung cancer with computed tomography: protocol for systematic reviews for the Canadian Task Force on Preventive Health Care  \nJennifer Pillay1* , Sholeh Rahman 1, Scott Klarenbach2, Donna L. Reynolds3, Laure A. Tessier4, Guylène Thériault5, Nav Persaud6, Christian Finley7, Natasha Leighl8, Matthew D. F. McInnes9, Chantelle Garritty4, Gregory Traversy4, Maria Tan1 and Lisa Hartling1  \nAbstract  \nPurpose Lung cancer is the leading cause of cancer deaths in Canada, and because early cancers are often asymptomatic screening aims to prevent mortality by detecting cancer earlier when treatment is more likely to be curative. These reviews will inform updated recommendations by the Canadian Task Force on Preventive Health Care on screening for lung cancer.  \nMethods We will update the review on the benefits and harms of screening with CT conducted for the task  \nforce in 2015 and perform de novo reviews on the comparative effects between (i) trial-based selection criteria and use of risk prediction models and (ii) trial-based nodule classification and different nodule classification systems and on patients’ values and preferences. We will search Medline, Embase, and Cochrane Central (for questions on benefits and harms from 2015; comparative effects from 2012) and Medline, Scopus, and EconLit (for values and preferences from 2012) via peer-reviewed search strategies, clinical trial registries, and the reference lists of included studies and reviews. Two reviewers will screen all citations (including those in the previous review) and base inclusion decisions on consensus or arbitration by another reviewer. For benefits (i. e., all-cause and cancer-specific mortality and health-related quality of life) and harms (i. e., overdiagnosis, false positives, incidental findings, psychosocial harms from screening, and major complications and mortality from invasive procedures as a result of screening), we will include studies of adults in whom lung cancer is not suspected. We will include randomized controlled trials comparing CT screening with no screening or alternative screening modalities (e. g., chest radiography) or strategies (e. g., CT using different screening intervals, classification systems, and/or patient selection via risk models or biomarkers); non-randomized studies, including modeling studies, will be included for the comparative effects between trial-based and other selection criteria or nodule classification methods. For harms (except overdiagnosis) we will also include non-randomized and uncontrolled studies. For values and preferences, the study design may be any quantitative design that either directly or indirectly measures outcome preferences on outcomes pertaining to lung cancer screening. We will only include studies conducted in Very High Human Development Countries and having full texts in English or French. Data will be extracted by one reviewer with verification by another, with the exception of result  \n*Correspondence: Jennifer Pillay [jpillay@ualberta.ca](jpillay@ualberta.ca)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regul","cbCaiaJ6vbzIt2wJ","https://ap.wps.com/l/cbCaiaJ6vbzIt2wJ","pdf",1069666,18,"English","# Purpose\n# Methods\n## Evidence sources and search strategy\n## Study selection and outcomes\n## Data extraction, pooling, and bias assessment\n# Discussion","[{\"question\":\"What is the purpose of this protocol for lung cancer screening?\",\"answer\":\"It aims to prevent lung cancer mortality by enabling earlier detection through computed tomography screening, and to inform updated recommendations for the Canadian Task Force on Preventive Health Care.\"},{\"question\":\"Which comparative questions will the review address?\",\"answer\":\"It will compare trial-based selection criteria versus risk prediction models, and trial-based nodule classification versus other classification systems, and also assess patient values and preferences.\"},{\"question\":\"How will evidence quality and study bias be assessed?\",\"answer\":\"Two reviewers will independently assess within- and across-study risk of bias and rate certainty using GRADE, then reach consensus.\"}]","Screening for lung cancer with computed tomography - protocol for systematic reviews - Canadian Task Force on Preventive Health Care | PDF",1790007464,45]